Clinical trials: Intravitreal Injections
Leber Hereditary Optic Neuropathy
A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy
This study is meant to evaluate the safety and efficacy of rAAV2-ND4 treatment for Leber hereditary optic neuropathy with the G11778A mutation in mitochondrial DNA.
- Trial name
- NCT03153293
- Testing
- rAAV2-ND4
- Where
- China
- Volunteers
- 159 people
- Sponsor
- Huazhong University of Science and Technology
Retinoblastoma
Intravitreal Injections of Melphalan for Retinoblastoma
Retinoblastoma treatment has become more and more focused in the last years. New treatments developed by Dr. Kaneko from Japan in 1995 are now being tested in clinical trials.
- Trial name
- NCT01558960
- Testing
- IVit Melphalan
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Hadassah Medical Organization
Central Retinal Vein Occlusion, Choroidal Neovascularization
A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye
This is a research study to evaluate the effects of repeated intravitreal injections on bacteria around the eye.
- Conditions
- Central Retinal Vein Occlusion, Choroidal Neovascularization, Age-related Macular Degeneration, Branch Retinal Vein Occlusion
- Trial name
- NCT01531842
- Testing
- Conj flora Antibiotic resistance
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mid Atlantic Retina
Angioid Streaks, Choroidal Neovascularization
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks
- Trial name
- NCT00599820
- Testing
- Intravitreal Bevacizumab
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Stargardt Disease
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease
- Trial name
- STARLIGHT (NCT05417126)
- Testing
- Gene Therapy-vMCO-010
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Nanoscope Therapeutics Inc.
Age-Related Macular Degeneration
IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD
This is a prospective, single-blind, randomized study to evaluate intravitreal aflibercept injection (IAI) versus sham as prophylaxis against conversion to neovascular age-related macular degeneration (AMD) in "high-risk"…
- Trial name
- PRO-CON (NCT02462889)
- Testing
- Intravitreal aflibercept injection
- Where
- 4 sites in United States
- Volunteers
- 128 people
- Sponsor
- Jeffrey S Heier
Optic, Atrophy, Hereditary, Leber
Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)
The goal of this clinical trial is to assess the effectiveness of GS010, a gene therapy, in improving the visual outcome in participants with Leber Hereditary Optic Neuropathy (LHON) due to the G11778A ND4 mitochondrial mutation…
- Trial name
- REVERSE (NCT02652780)
- Testing
- GS010
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 37 people
- Sponsor
- GenSight Biologics
Retina Disease, Retinopathy of Prematurity
Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity
Despite advances in the neonatal intensive care units, retinopathy of prematurity (ROP) has become a common reason for blindness and visual disabilities in premature infants so that it accounts for about 5% and 30% of such…
- Conditions
- Retina Disease, Retinopathy of Prematurity, Ranibizumab
- Trial name
- NCT05701124
- Testing
- Ranibizumab (0.25 mg/0.025 mL)
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Zagazig University
Leber Hereditary Optic Disease
Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients
The goal of this Clinical trial is to assess the safety and efficacy of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy (LHON)
- Trial name
- REVISE (NCT07303296)
- Testing
- GS010 High dose, GS010 Low dose
- Where
- France
- Volunteers
- 14 people
- Sponsor
- GenSight Biologics
Retinitis Pigmentosa, Usher Syndrome Type 2
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- NCT05158296
- Testing
- Ultevursen
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 7 people
- Sponsor
- Laboratoires Thea
Refractory Diabetic Macular Edema
The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema
after advent of RD photoreceptor degeneration Occurred. This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened .
- Trial name
- NCT03821168
- Testing
- injection of bevacizumab and erythropoietin, injection of bevacizumab
- Where
- Iran
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Retinal Astrocytic Hamartoma
Sirolimus for Retinal Astrocytic Hamartoma
A single patient study using intravitreal Sirolimus to treat a patient with multiple retinal astrocytic hamartomas (RAH) of both eyes.
- Trial name
- NCT04707209
- Testing
- Sirolimus
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- The Hospital for Sick Children
Stargardt Disease
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
The current study is a non-interventional long-term safety follow-up of the subjects who completed STARLIGHT, in accordance with FDA guidance on recipients of human gene therapy products.
- Trial name
- SUSTAIN (NCT06048185)
- Testing
- Gene Therapy Product-MCO-010
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Nanoscope Therapeutics Inc.
Macular Edema (ME)
To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
To evaluate the efficacy and safety of 0.5 mg Ranibizumab intravitreal injections in adult patients with visual impairment due to macular edema (ME).
- Trial name
- NCT01846299
- Testing
- Ranibizumab
- Where
- 61 sites in Australia, Belgium and 17 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Circumscribed Choroidal Haemangioma
Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma
The aim of this study was to investigate the safety and effectiveness of application of intravitreal conbercept injection as the primary treatment for exudative circumscribed choroidal haemangioma.
- Trial name
- IVCCCH (NCT03973125)
- Testing
- conbercept
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Retinopathy of Prematurity (ROP)
Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity: A Prospective Interventional Case Series
Aggressive posterior retinopathy of prematurity (AP-ROP) is a severe form of retinopathy of prematurity that can progress rapidly and lead to retinal detachment and permanent vision loss if not treated promptly.
- Trial name
- NCT07721298
- Testing
- Intravitreal Ranibizumab injection
- Where
- Egypt
- Volunteers
- 39 people
- Sponsor
- Ain Shams University
Leber Hereditary Optic Neuropathy
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
This study is meant to assess the safety and efficacy of rAAV2-ND4 treatment of Leber hereditary optic neuropathy with 11778 LHON mutation.
- Trial name
- rAAV2-ND4 (NCT01267422)
- Testing
- rAAV2-ND4
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Bin Li
Circumscribed Choroidal Haemangioma
Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma
This prospective clinical trial aims to evaluate the safety and effectiveness study of intravitreal conbercept injection for exudative circumscribed choroidal haemangioma.
- Trial name
- NCT03571282
- Testing
- conbercept
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Inherited Retinal Diseases
Extension Study of the PUMCH-E101 Clinical Trial：Safety and Efficacy Study of PUMCH-E101 Injection in the Contralateral Eye
The goal of this clinical trial is to evaluate the safety and efficacy of PUMCH-E101 injection in the contralateral eye of subjects with RDH12 retinopathy.
- Trial name
- NCT07878572
- Testing
- PUMCH-E101 Injection(High dose)
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Peking Union Medical College Hospital
Age-related Macular Degeneration, Diabetic Macular Edema
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on circulating vascular endothelial growth factor.
- Conditions
- Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02118831
- Testing
- Blood Sample Collection, Aflibercept, Bevacizumab
- Volunteers
- 56 people
- Sponsor
- California Retina Consultants